The session titled “Immune Activation and Inflammatory Biomarkers (suPAR)” focused on how immune system activity and inflammation can be measured to assess health risks and guide preventive medicine. Eugen-Olsen explored immune activation and inflammatory biomarkers, highlighting suPAR as a strong indicator of systemic inflammation and biological risk.

The lecture examined how suPAR can enable earlier risk stratification, personalised prevention, and improved clinical decision-making within longevity and preventive healthcare.

Jesper Eugen-Olsen, PhD, is a Danish biochemist, inventor, and life-science entrepreneur who serves as Chief Scientific Officer and co-founder of ViroGates, a medtech company dedicated to improving patient outcomes through innovative prognostic biomarkers. He holds a PhD in Biochemistry from the University of Copenhagen and brings more than 30 years of research experience, with over 200 peer-reviewed publications and multiple patents. In addition to his corporate leadership, he acts as an independent expert and evaluator for EU-funded projects and previously served as Director of Laboratory Research at Copenhagen University Hospital.

Eugen-Olsen is widely recognized for discovering the clinical utility of the biomarker suPAR, originally identified in HIV research and now validated in hundreds of studies as a prognostic marker across multiple diseases. His work focuses on inflammation, immune activation, and disease prognosis, supporting clinicians in identifying patient risk and improving care pathways. He is a senior scientist at the University of Copenhagen and a principal investigator at Copenhagen University Hospital Hvidovre, and he is also a patent inventor on technologies including suPAR and IP-10. As a shareholder in ViroGates, he contributes to the commercialization of the suPARnostic® diagnostic product line.